AllianceBernstein’s Perspective Therapeutics CATX Stock Holding History

AllianceBernstein’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$501K	Buy	120,030 +36,560	+44%	+$138K	﹤0.01%	2711
2026 Q1	$230K	Hold	83,470	–	–	﹤0.01%	2991
2025 Q4	$230K	Hold	83,470	–	–	﹤0.01%	3009
2025 Q3	$286K	Hold	83,470	–	–	﹤0.01%	2955
2025 Q2	$287K	Buy	83,470 +33,780	+68%	+$89.2K	﹤0.01%	2936
2025 Q1	$106K	Hold	49,690	–	–	﹤0.01%	3062
2024 Q4	$159K	Hold	49,690	–	–	﹤0.01%	3068
2024 Q3	$663K	Buy	49,690 +25,370	+104%	+$337K	﹤0.01%	2521
2024 Q2	$242K	Buy	+24,320	New	+$352K	﹤0.01%	2986
2014 Q2	–	Sell	-50	Closed	-$1K	–	3433
2014 Q1	$1K	Buy	+50	New	+$509	﹤0.01%	3518

Other funds holding CATX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SSC

Spruce Street Capital New York $510M AUM

AllianceBernstein's CATX Position: Q2 2026 in Review

AllianceBernstein increased its Perspective Therapeutics (CATX) stake by 44% in Q2 2026, buying an estimated $138K and bringing the position to 120,030 shares worth $501K. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

AllianceBernstein first reported a position in CATX in Q1 2014 and has held it in 10 quarters since. The position peaked at $663K in Q3 2024. 132 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

AllianceBernstein held 120,030 shares of Perspective Therapeutics worth $501K as of Q2 2026.
AllianceBernstein bought 36,560 Perspective Therapeutics shares in Q2 2026, an estimated $138K.
Perspective Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2711 holding.
AllianceBernstein first reported a position in Perspective Therapeutics in Q1 2014 and has held it in 10 quarters since.
AllianceBernstein's Perspective Therapeutics position peaked at $663K in Q3 2024.
132 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.